Homepage Top Section2

This investigational ribonucleic acid interference (RNAi) therapeutic is aimed at treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The FDA has set a prescription drug user fee act (PDUFA) action

The approval makes the company the first commercial biotech to receive such a license for this cell therapy type. Derived from the umbilical cord blood of humans, the

The funding is set to enhance the company’s C1 protein production platform to enable rapid, cost-effective production of mAbs. This initiative focuses on diseases like RSV and malaria,

This partnership aims to address the global obesity epidemic by fast-tracking an innovative therapy that could improve the lives of millions. It includes the progression of LAE102 through

This small interfering ribonucleic acid (RNA)[siRNA] therapy is designed to combat one of the ALS subtypes, FUS-ALS, by reducing FUS protein levels. RAG-21 leverages RNA interference (RNAi) technology

This rare genetic disease currently lacks FDA-approved treatments, making the submission a significant milestone. Plozasiran, also known as ARO-APOC3, is an investigational RNA interference (RNAi) therapeutic. It aims

Under the agreement, Kaken has secured an option to acquire commercial rights to the antibody in select Asian territories. In return, the company will fund the preclinical and

The FDA has set a target action date of 18 April 2025 for its decision. If approved, Dupixent is expected to become the first targeted CSU therapy in

This grant will aid the progression of ASHA-624 towards first-in-human clinical trials. Designed using the company’s PRISM drug design technology, it is a brain-penetrant intra-molecular glue inhibitor of